Category: Uncategorized

13 Sep 2018


Apple launched a large-scale heart rate study in collaboration with Stanford Medicine in November 2017. The study (called Apple Heart Study) was conducted to improve technology that identifies irregular heart rhythms. Early diagnosis and treatment can prevent life-threatening heart complications, including strokes.

The study was carried out in the form of an app, open to all Apple Watch owners in the United States, 22 years and older, with a Series 1 or above. It measured heart rhythm and heart rate using the Apple Watch’s LED sensor and light-sensitive photodiodes to detect the amount of blood flowing through a person’s wrist. It was able to isolate heart rhythms from other noise in order to detect irregular heartbeats, with the use of AI technology.

The study was closed to new participants at the start of last month, with Apple also informing some users who signed up that their contribution is complete. The end is in sight as the study is expected to come to a conclusion in January 2019.

It is still unclear as to what Apple and Stanford Medicine will do with the results from their study, and if it will be utilized to equip future Apple Watch devices to bring the results into effect.

For more information visit Cult of Mac

09 Aug 2016

CDISC and TransCelerate Announce New Standard for Breast Cancer

TransCelerate BioPharma Inc.(“TransCelerate”) is a non-profit organisation dedicated to improving the health of people around the world by accelerating and simplifying the research and development (R&D) of innovative new therapies.The Clinical Data Interchange Standards Consortium (CDISC) is a 501(c)(3) global non-profit charitable organisation that streamlines research and enables connections to healthcare through the development of clinical research data standards.

The need to rapidly and efficiently share new data within clinical research is one of the key initiatives within the world of clinical trial innovation and efficiencies. One of the major steps forward is the announcement CDISC and TransCelerate made earlier this year regarding the open availability of a new CDISC Therapeutic Area Standard for Breast Cancer.

“In order to optimize the care of any patient, we need to have a common set of information that is reliably collected on every one,” stated Dr. Laura Esserman, University of California San Francisco breast cancer surgeon and one of Time magazine’s top 100 most influential individuals in the world. “The CDISC standards will help us to ensure that we are all using a common language, which will then usher in an era where we can automate quality improvement, trial matching, seamless integration of data into trials, and streamline the process of improving the care, survival, and quality of life of our patients.”

For the full article please visit :